9 results about "Immuno assay" patented technology

One aspect of the invention provides a method for detecting a target organism in a sample, the method comprising: a. Optionally immobilizing the target organism on a solid phase; b, incubating the target organism and one or more reporter enzyme detection probes together to form one or more target organism-enzyme detection probe compounds; c, removing any uncombined reporter enzyme detection probe; d. Contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium, to generate one or more detectable products in the diffusion rate limiting medium; and e. Detecting the one or more detectable products by detecting the visible spots.

The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42 / 40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS / MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42 / 40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.

An embodiment relates to a centrifugal immunoassay device for multiple diagnoses for detecting an object to be detected from a sample through centrifugation, the device including: a centrifugal cartridge having a plurality of wells in which the sample is received; a rotating part rotating in a state of mounting the centrifugal cartridge thereon; an absorbance optical system coupled to the centrifugal cartridge to measure the absorbance of the object to be detected received in a detection well among the plurality of wells of the centrifugal cartridge; a syringe adapted to be inserted into the centrifugal cartridge, suck the object to be detected, and discharge the sucked object to the detection well; and a housing for surrounding the centrifugal cartridge, the rotating part, the absorbance optical system, and the syringe.

This invention relates to a quantitative method for polyion-selective electrodes, specifically a novel method for rapid, accurate, and sensitive quantification based on the initial potential change rate of a polyion-selective electrode. Using an all-solid-state ultrathin polymer membrane polyion-selective electrode as the working electrode, it is inserted into the sample to be tested, causing the target polyions to accumulate at the membrane interface, generating an initial potential change rate. The concentration of polyions in the sample is then obtained based on the corresponding value of the initial potential change rate of the sample on a standard curve. This novel quantitative method for polyion-selective electrodes developed in this invention has advantages such as simple operation, short detection time, low operating cost, and suitability for on-site detection. It is of great significance for the direct potential determination of polyions and for counterion determination, enzyme assays, and immunoassays using polyion electrodes as signal converters.

The invention provides a high-sensitivity multi-index protein detection instrument based on an OECT and ELISA combined technology, belongs to the technical field of biomedical detection, and is characterized in that the high-sensitivity multi-index protein detection instrument comprises: an integrated carrier plate, which comprises a plurality of units, and each unit is provided with a detection unit and an immunoreaction unit in an integrated manner; the immunoreaction unit is used for generating small molecules related to the target protein concentration; the trapping agents coated by the at least two immunoreaction units are different; the detection unit comprises an organic electrochemical transistor, and the organic electrochemical transistor generates changing electric signals; the hardware circuit system is used for collecting electric signals; and the upper computer is in communication connection with the hardware circuit system and is used for receiving the electric signal and displaying a detection result related to the target protein concentration based on the electric signal. According to the invention, a miniaturized instrument integrating immune reaction and immunoassay functions and capable of performing multi-index protein high-sensitivity detection is realized.

A method of performing an immunoassay with an automated clinical analyzer, includes, creating an assay mixture utilizing an analyte from a patient sample, a first reagent having a plurality of particles configured to specifically bind to the analyte and a second reagent having an enzyme. The method further includes incubating the assay mixture and then performing a wash cycle on the assay mixture to retain the plurality of particles while removing the remaining portion of the assay mixture not bound the plurality of particles. The method further includes selecting a first substrate material or a second substrate material. The method further includes obtaining the selected substrate material and adding the selected substrate material with the plurality of particles remaining from the wash cycle to create a signal generating mixture. The method further includes incubating the signal generating mixture and analyzing the signal generating mixture with a luminometer.

A system includes an anti-allergen formulation and a device that generates droplets of the formulation to be delivered to an air environment. The aqueous formulation comprises an organic acid having a vapor pressure of between 0.001 Pa and 172 Pa and a water solubility of at least 24.99 grams of organic acid per 100 grams of water at both room temperature and standard pressure. The device can produce droplets of the formulation having a median particle size (Dv50) of no greater than 120 microns. Formulations delivered as droplets in an air environment, as measured by enzyme-linked immunoassay, can provide a statistically significant reduction of one or more airborne allergens compared to a control. In addition, the formulations delivered as droplets in the air environment can effectively neutralize more than 50% of one or more airborne allergens present in the air environment.

The present invention relates to macromolecular blockers of non-specific interactions of an analyte and other components of the analytical system with the solid phase, which considerably decreases the non-specific interactions during the assay. The macromolecular blocker comprises synthetic copolymer or homopolymer, selected from the group comprising polyacrylamide, polymethacrylamide, polyacrylate, polymethacrylate, poly(N-(2- hydroxypropyl)methacrylamide), poly(2-oxazoline); to which at least one hydrophobically-active anchor is attached via a covalent bond, said hydrophobically-active anchor enabling suppression of non-specific interactions in immuno assays. The invention further relates to a method of preparing and to the use of said macromolecular blockers for capturing of specific antibodies or antigens or other molecules on the surface of the solid phase. The present invention enables to replace animal-derived proteins with a synthetic macromolecular blocker that is not only more effective in blocking activity itself, but it is also defined in its structure, has high batch-to-batch reproducibility, and does not need to be tested for the presence of viruses and other pathogens.

The application provides a soluble growth stimulating expression gene 2 protein determination kit, a preparation method and an application, and belongs to the technical field of biochemical immunoassay. The application adopts a latex enhanced immunoturbidimetry to detect the soluble growth stimulating expression gene 2 protein, optimizes and adjusts key components of reagent 1 and reagent 2, obtains optimal components and concentrations of polyanions, surfactants, accelerators and biochemical cross-linking agents, solves technical problems such as poor stability of sST2 related reagents and incapability of meeting high value detection accuracy of sST2 greater than 400 ng / mL, and the optimal components and concentrations can significantly improve the detection accuracy of high values in a linear range of 5 ng / mL to 432 ng / mL, in particular, the prepared sST2 latex reagent has sensitivity, anti-interference ability, stability, repeatability and pre-band reaching and being superior to third-party reagents, and can well meet the demand of clinical use.